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LETTER TO THE EDITOR
Response to the letter from Dr Shelton
Sir - Dr Shelton suggests that the slightly greater relative risk
of breast cancer that we observed in developing countries
(1.24) than that observed in developed countries (1.07) may
have occurred because hospital controls in developing count-
ries have chronic underlying medical conditions (such as
tuberculosis, fungal infections, malaria, prior severe trauma,
etc.) which may be inversely related to the use of oral contra-
ceptives. Furthermore, he hypothesises that these controls
might use oral contraceptives less for two reasons: decrease
in sexual activity due to chronic conditions, and a reluctance
by health practitioners to prescribe oral contraceptives to
controls because of their chronic health problems. Either of
these situations would lead to spuriously inflated relative
risks for breast cancer among oral contraceptive users in
developing countries.
Although we stated in our paper that a combination of
chance and minor sources of bias and confounding could
account for our results, we do not agree that Dr Shelton
provides a reasonable explanation for our findings. Although
our observation that the prevalence of oral contraceptive use
did not vary appreciably across diagnostic categories of con-
trols could be interpreted as evidence that the hypothesised
phenomenon is operative for all controls, if true it would
presumably be operative in cases as well, and thus lead to no
bias in our results. However, we still consider our interpreta-
tion to be a more plausible one, i.e. that similar proportions
of oral contraceptive users among the different diagnostic
categories of controls is evidence against the controls pro-
viding an underestimate of the expected amount of use in the
cases. Our controls included women with a broad range of
disease, both acute and chronic, and we consider it highly
unlikely that all would be subjected to the same forces Dr
Shelton hypothesised to a similar degree in multiple coun-
tries.
We presented additional evidence against the hypothesised
bias. Information regarding each subject's prior medical his-
tory (history of tuberculosis, jaundice, thromboembolism,
etc.) and indices of medical care utilisation (number of chest
X-rays and prior pap smears) were considered as potential
confounding variables, and none was found to be such. We
also investigated as potential confounders a number of sexual
variables, which would presumably be related to need for
contraception; and none of these had confounding effects on
the relationship between breast cancer and oral contracep-
tives.
The suggestion was also made that the increased risk seen
in recent oral contraceptive users could be related to the
controls' current disease status, which may have precluded
their recent use of oral contraceptives. If this were true, oral
contraceptive use would vary across diagnostic groups in the
controls. Also, if this tendency were a recent phenomenon, as
suggested, then it would have had little effect on our results
because data collection began over 10 years ago, and the
bulk of the data was collected several years in the past.
Dr Shelton also suggests that our findings of an increased
risk in recent users could be due to screening bias. As
indicated in our paper, if this bias were operative, one would
expect such users to tend to have small, early stage tumours;
but we found increases in risk in relation to current and
recent use of oral contraceptives for tumours of all sizes.
It was suggested that a complete description of both
admission and underlying diagnoses of controls and possible
information on previous hospital admissions be provided. As
indicated above, both indices of medical care and inform-
ation on prior medical conditions, as well as admission diag-
noses of controls, were considered. It is always a matter of
judgement as to how much information to include in a paper.
Since the report is lengthy as published, we elected not to
present this detailed information, but it can be made
available on request.
Dr Shelton also expressed concern that the bias he
hypothesised may have been an explanation for the higher
relative risks observed in Chiang Mai than elsewhere. We
investigated the Chiang Mai results in great detail and, as
explained in the report, could find no evidence that the high
relative risk observed in that center was due to any of the
many possible sources of bias considered. Chance is the most
likely explanation. In an updated set of data from the WHO
study, we attempted to replicate Table III in our paper, and
the findings for Chiang Mai were less striking (the overall
findings, however, are unchanged).
Finally, let us emphasise that we are not merely attempting
to explain difference in relative risks of 1.07 (for developed
countries) and 1.24 (for developing countries). As shown in
Table VIII of the paper, the associations between breast
cancer and various features of oral contraceptive use, (i.e.
duration, recency and latency) are all stronger for developing
than developed countries. Also, as shown in Table III, there
was remarkable consistency of results among countries.
We will only know whether our results for developing
countries represent a true effect of oral contraceptives on risk
of breast cancer if they are replicated by others. It is thus of
considerable relevance that recent population-based
case-control studies in China (Yuan et al., 1988) and Costa
Rica (Lee et al., 1987) have also shown increased risks of
breast cancer in oral contraceptive users.
Lastly, additional analysis of the histological features of
the breast cancers in the WHO study have provided a poss-
ible biological interpretation for our findings (Stalsberg et al.,
1989); i.e. that the lobular epithelium in the breast of women
in developing countries is already maximally stimulated to
proliferate, and oral contraceptives therefore have no further
impact, whereas the lobular epithelium of women in low risk
population is not maximally stimulated so that oral cont-
raceptives can exert an additional effect in causing prolifera-
tion in the lobular mammary epithelial cells.
We do not contend that the results from the WHO study
are infallible. These results do, however, raise serious ques-
tions that warrant further investigation, and are not likely
due to the sources of bias suggested by Dr Shelton.
Yours etc.
D.B. Thomas & E.A. Noonan,
Program in Epidemiology,
Fred Hutchinson Cancer Research Center,
Division of Public Health Services,
1124 Columbia Street,
Seattle, WA 98104, USA.
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